Pathkey.ai Ltd (PKY) - Total Assets
Based on the latest financial reports, Pathkey.ai Ltd (PKY) holds total assets worth AU$513.28K AUD (≈ $363.18K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Pathkey.ai Ltd net assets for net asset value and shareholders' equity analysis.
Pathkey.ai Ltd - Total Assets Trend (1996–2025)
This chart illustrates how Pathkey.ai Ltd's total assets have evolved over time, based on quarterly financial data.
Pathkey.ai Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Pathkey.ai Ltd's total assets of AU$513.28K consist of 97.1% current assets and 3.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$107.50K | 0.0% |
| Accounts Receivable | AU$56.77K | 11.1% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$15.16K | 3.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Pathkey.ai Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PKY stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pathkey.ai Ltd's current assets represent 97.1% of total assets in 2025, an increase from 52.7% in 1996.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, down from 51.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is cash and equivalents at 0.0% of total assets.
Pathkey.ai Ltd Competitors by Total Assets
Key competitors of Pathkey.ai Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$17.99 Million |
|
Cegedim S.A.
PA:CGM
|
France | €986.89 Million |
|
Diagnos Inc
V:ADK
|
Canada | CA$1.17 Million |
|
Intelicare Holdings Ltd
AU:ICR
|
Australia | AU$1.64 Million |
|
Adheris Health Limited
AU:AHE
|
Australia | AU$39.84 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$23.68 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
Pathkey.ai Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.64 | 0.77 | 8.40 |
| Quick Ratio | 0.64 | 0.77 | 8.40 |
| Cash Ratio | 0.14 | 0.75 | 0.00 |
| Working Capital | AU$-283.53K | AU$-114.00K | AU$2.14 Million |
Pathkey.ai Ltd - Advanced Valuation Insights
This section examines the relationship between Pathkey.ai Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 24.7% |
| Total Assets | AU$513.28K |
| Market Capitalization | $339.12 USD |
Valuation Analysis
Below Book Valuation: The market values Pathkey.ai Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pathkey.ai Ltd's assets grew by 24.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pathkey.ai Ltd (1996–2025)
The table below shows the annual total assets of Pathkey.ai Ltd from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$513.28K ≈ $363.18K |
+24.70% |
| 2024-06-30 | AU$411.60K ≈ $291.23K |
0.00% |
| 2023-06-30 | AU$411.60K ≈ $291.23K |
-41.99% |
| 2022-06-30 | AU$709.58K ≈ $502.07K |
-27.54% |
| 2021-06-30 | AU$979.22K ≈ $692.86K |
-60.87% |
| 2020-06-30 | AU$2.50 Million ≈ $1.77 Million |
+167.41% |
| 2019-06-30 | AU$935.77K ≈ $662.12K |
+183.43% |
| 2018-06-30 | AU$330.15K ≈ $233.60K |
-83.77% |
| 2017-06-30 | AU$2.03 Million ≈ $1.44 Million |
+223.44% |
| 2016-06-30 | AU$628.78K ≈ $444.90K |
-74.23% |
| 2015-06-30 | AU$2.44 Million ≈ $1.73 Million |
-58.92% |
| 2014-06-30 | AU$5.94 Million ≈ $4.20 Million |
-31.01% |
| 2013-06-30 | AU$8.61 Million ≈ $6.09 Million |
-16.19% |
| 2012-06-30 | AU$10.27 Million ≈ $7.27 Million |
-34.51% |
| 2011-06-30 | AU$15.69 Million ≈ $11.10 Million |
+818.04% |
| 2010-06-30 | AU$1.71 Million ≈ $1.21 Million |
+314.48% |
| 2009-06-30 | AU$412.32K ≈ $291.74K |
-99.56% |
| 2008-06-30 | AU$93.76 Million ≈ $66.34 Million |
+16.93% |
| 2007-06-30 | AU$80.19 Million ≈ $56.74 Million |
+48.96% |
| 2006-06-30 | AU$53.83 Million ≈ $38.09 Million |
+264.38% |
| 2005-06-30 | AU$14.77 Million ≈ $10.45 Million |
-20.74% |
| 2004-06-30 | AU$18.64 Million ≈ $13.19 Million |
+72.21% |
| 2003-06-30 | AU$10.82 Million ≈ $7.66 Million |
+4.61% |
| 2002-06-30 | AU$10.35 Million ≈ $7.32 Million |
+7.72% |
| 2001-06-30 | AU$9.61 Million ≈ $6.80 Million |
-0.67% |
| 2000-06-30 | AU$9.67 Million ≈ $6.84 Million |
+36.08% |
| 1999-06-30 | AU$7.11 Million ≈ $5.03 Million |
+9.32% |
| 1998-06-30 | AU$6.50 Million ≈ $4.60 Million |
+2.03% |
| 1997-06-30 | AU$6.37 Million ≈ $4.51 Million |
-5.96% |
| 1996-06-30 | AU$6.77 Million ≈ $4.79 Million |
-- |
About Pathkey.ai Ltd
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The com… Read more